| Document |
Document Title |
|
WO/2007/028809A1 |
Disclosed is a method for producing dioxolane by reacting ethylene glycol (1) with formaldehyde in aqueous solution (2) in the presence of catalysts. Said method is characterized in that the reaction is carried out in a reactive distilla...
|
|
WO/2007/027651A2 |
The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, metabolic syndrome , hyperinsul...
|
|
WO/2007/020964A1 |
Disclosed is a method for producing a 4-halocatechol compound, which is characterized in that a catechol compound is reacted with 1,3-dihalo-5,5-dimethylhydantoin. Also disclosed are a high-purity 4-chloromethylenedioxybenzene which is c...
|
|
WO/2007/017092A1 |
The present invention relates to novel substituted 4-benzyloxy-benzoic acid amide derivatives, processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold M...
|
|
WO/2007/017093A1 |
The present invention relates to novel substituted 2-benzyloxy-benzoic acid amide derivatives, processes for their preparation, and their use in medicaments, especially for the prophylaxis and treatment of diseases associated with Cold M...
|
|
WO/2007/014958A1 |
A process for the catalytic carboxylation of alkylene oxides with carbon dioxide, in the presence of a catalytic composition and water, wherein the catalyst composition comprises an alkali metal halide and a macrocyclic chelating compound.
|
|
WO/2007/016431A2 |
The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess un...
|
|
WO/2007/013201A1 |
A zinc fluorescent probe that excels in water solubility, enabling observing with high sensitivity of any change of intracellular zinc ion level ratiometrically with the use of a single excited wavelength; a process for producing the sam...
|
|
WO/2007/012641A1 |
A new process for synthesising 3,4-dioxo-substituted aromatic aldehydes by Oppenauer oxidation of the corresponding benzyl alcohols is described. The process, which specifically uses formaldehyde as hydrogen acceptor, proceeds with unexp...
|
|
WO/2007/009636A1 |
The invention relates to 1,2,3,6,7,8-hexahydro-s-indacene-derivatives and 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-derivatives of formula (I), wherein R1, A1, Z1, n, X and Y have the meaning defined in the claims. The invention also relat...
|
|
WO/2007/010990A1 |
It is intended to provide a method whereby fullerene 1,3-dioxolane is conveniently produced at a high yield. Namely, fullerene 1,3-dioxolane is produced by reacting fullerene oxide with a carbonyl compound in the presence of a solid acid...
|
|
WO/2007/008994A2 |
The present invention relates to compounds of the formula (I), which are modulators of metalloproteinase activity. and pharmaceutically acceptable salts thereof, wherein W is -C(O)-, -OC(O)-, -NHC(O)-, -C(O)O-, Or -C(O)NH-; R1 is phenyl,...
|
|
WO/2007/004740A1 |
The invention relates to a sensory stimulant composition containing one or more of vanillin acetals represented by the general formula (1), and a flavor and fragrance composition, a beverage or food product, a fragrance or cosmetic produ...
|
|
WO/2007/001015A1 |
[PROBLEMS] To provide: a process for producing an optically active aminopentane derivative which is expected to be useful as a psychotropic agent, an antidepressant, an anti-Perkinson agent, an anti-Alzhemer disease, an anti-apoptotic ag...
|
|
WO/2006/136502A1 |
The present invention relates to compounds of formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, for use as therapeutically active substances. The compounds are usef...
|
|
WO/2006/135978A1 |
The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.
|
|
WO/2006/134955A1 |
A compound represented by the general formula (1) or (100), a salt thereof or a hydrate of the compound or salt, which is excellent in cell adhesion-inhibitory effect and cell infiltration-inhibitory effect: (1) (100) wherein R10 represe...
|
|
WO/2006/133339A2 |
Monoamine re-uptake inhibitors and more specifically serotonin and noradrenaline re-uptake inhibitors are disclosed that have utility in the treatment of disorders of the central or peripheral nervous system in both men and women. The co...
|
|
WO/2006/131465A1 |
The present invention pertains to a reversibly thermochromic system comprising a substituted or an unsubstituted 6,11-dihydroxy-naphthacene-5,12-dione and a base and to a reversibly thermochromic composition comprising the reversibly the...
|
|
WO/2006/119907A1 |
The present invention relates to the technical purification of vinylene carbonate (VC) by means of a simple thermal treatment with organic compounds which possess amidic nitrogen-hydrogen bonds, followed by a distillation and a melt crys...
|
|
WO/2006/119911A1 |
The present invention relates to the industrial production of vinylene carbonate (VC) by elimination of hydrogen chloride from chloroethylene glycol carbonate (CGC) with tertiary amines in the absence of relatively large additional amoun...
|
|
WO/2006/121095A1 |
A pharmaceutical composition comprising a compound having the general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient: (I) wherein R1 represents a C6-C10 aryl group which may be substituted by a residu...
|
|
WO/2006/120343A2 |
The invention relates to a surface treatment method, in which a material other than the human body, which is selected from metallic materials and fibrous materials, is brought into contact with a composition comprising at least one dianh...
|
|
WO/2006/120342A2 |
The invention relates to a method for the treatment of a material other than the human body, in which the material to be treated is mixed or brought into contact with a composition comprising: a) at least one compound A which is selected...
|
|
WO/2006/119908A1 |
Method of storing and transporting vinylene carbonate, characterized in that the vinylene carbonate possesses a stabilizer content of less than 100 ppm, has a degree of purity of 99.9% to 99.99999%, and is in the solid aggregate state.
|
|
WO/2006/120639A2 |
The present invention relates to the field of organic synthesis. More particularly it provides a process for making aromatic non-conjugated enol esters or enol ethers from an aromatic compound or moiety and a protected enal compound or m...
|
|
WO/2006/119910A1 |
The present invention relates to the industrial purification of vinylene carbonate (VC). It has been found advantageous to subject the impure VC, prior to purifying distillation, to a simple thermal treatment with organic compounds which...
|
|
WO/2006/120178A1 |
The present invention relates to compounds of formula I, in which at least one of R5, R6 and R7 is SR12, S(O)R12 or S(O)2R12 group where R12 is a C1-6haloalkyl group, that act, as chemical uncouplers. Compounds of the invention are usefu...
|
|
WO/2006/119909A1 |
The present invention relates to the industrial production of vinylene carbonate (VC) by elimination of hydrogen chloride from chloroethylene glycol carbonate (CGC) over solid catalysts in the gas phase, the reaction being carried out ov...
|
|
WO/2006/117611A1 |
The present patent application concerns new compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1 -4 alkylene and B a C3-4...
|
|
WO/2006/118014A1 |
Disclosed is a method for producing a 4,4'-bicyclohexanedione monoketal represented by the general formula (2) with high yield by a simple operation. In this method, 4,4'-bicyclohexanedione and a diol are reacted in the liquid phase in t...
|
|
WO/2006/116158A1 |
Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of R1, R2, R3, R4, y, n, m, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of...
|
|
WO/2006/103527A1 |
The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical...
|
|
WO/2006/103689A1 |
The present invention discloses a process for the synthesis of N-[4-Cyano-3-(trifluoromethyl) phenyl]-3-[(4-fluorophenyl) sulphonyl]-2-hydroxy-2-methyl propanamide (Form I). The invention discloses a reagent for oxidation of N-[4-Cyano-3...
|
|
WO/2006/102760A1 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.
|
|
WO/2006/097500A1 |
A bridged metallocene compound of formula (I) wherein: M is a transition metal; X, is a hydrogen atom, a halogen atom, or a hydrocarbon group optionally containing hetematoms; L is a divalent bridging group; R1 is a linear C1C40 hydrocar...
|
|
WO/2006/097814A1 |
The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of: a) contacting a pro-chiral sulphide of formula (II) with...
|
|
WO/2006/098308A1 |
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...
|
|
WO/2006/093679A1 |
A coating composition for cationic curing comprises an epoxide, a multifunctional oxetane, a cationic photoinitiator and a cyclic carbonate at a higher level than has been used conventionally. This appears to have a synergistic effect, i...
|
|
WO/2006/093680A1 |
A sprayable energy-curable coating composition comprises an epoxide monomer or oligomer, a cationic photoinitiator and a cyclic carbonate, the cyclic carbonate being present in an amount of at least 7% by weight of the entire composition.
|
|
WO2006074025B1 |
Compounds of formula (I) : wherein, Z is -N-or>CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring mem...
|
|
WO/2006/087169A1 |
This invention relates to potentiation of the glutamate receptor by novel compounds of formula (I): The invention also relates to the use of the derivatives in treating diseases and conditions mediated by potentiation of the glutamate re...
|
|
WO/2006/088193A1 |
A therapeutic agent for a tumor selected from a hematopoietic tumor and a solid tumor, the therapeutic agent comprising, as the active ingredient, a benzoyl compound represented by the general formula (I) or a prodrug or pharmacologicall...
|
|
WO/2006/085149A2 |
Compounds of formulae (VIII), (IX), (X), (XI), (XII) (XIII), (XIV) and (XV), in which the variables are as defined in the claims are described, as well as methods, pharmaceutical compositions and kits for treating or preventing amyloid-r...
|
|
WO/2006/084688A1 |
Compounds of the formula (I): Wherein R1, R2, X and N are as defined in the specification; E is N, CH; A1 and A" are terminal groups as defined in the specification. The compounds have utility as HIV-I protease inhibitors.
|
|
WO/2006/081332A1 |
The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds having the formula: (see formula I) and pharmaceutically acceptable salts and/or esters thereof, wherein - n is 0, 1, 2, 3, or 4; - A, when present is a lower...
|
|
WO/2006/079653A1 |
The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative d...
|
|
WO/2006/075651A1 |
[PROBLEMS] To provide a process for efficiently producing the anti isomer of an optically active β-hydroxy-&agr -aminocarboxylic acid derivative useful as an intermediate for medicines/agricultural chemicals. [MEANS FOR SOLVING PROBLEMS...
|
|
WO/2006/076452A2 |
This application discloses a novel process for the synthesis of himbacine analogs, as well as the compounds produced thereby. The synthesis proceeds by alternative routes including the cyclic ketal amide route, the chiral carbamate amide...
|
|
WO/2006/067437A1 |
The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention...
|
